GW
VERV

GW & Wade’s Verve Therapeutics VERV Stock Holding History

GW & Wade’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$3.62M Hold
259,626
– – 0.12% 126
2023
Q3 		$3.44M Hold
259,626
– – 0.13% 118
2023
Q2 		$4.87M Hold
259,626
– – 0.18% 97
2023
Q1 		$3.74M Sell
259,626
-11
-0% -$215 0.14% 113
2022
Q4 		$5.02M Buy
259,637
+11
+0% +$291 0.21% 90
2022
Q3 		$8.92M Buy
+259,626
New +$8.29M 0.44% 70

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

GW & Wade's VERV Position: Q4 2023 in Review

GW & Wade held its Verve Therapeutics (VERV) position steady in Q4 2023 at 259,626 shares worth $3.62M. The position accounts for 0.12% of the portfolio, ranked #126.

GW & Wade first reported a position in VERV in Q3 2022 and has held it in 6 quarters since. The position peaked at $8.92M in Q3 2022. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • GW & Wade held 259,626 shares of Verve Therapeutics worth $3.62M as of Q4 2023.
  • GW & Wade left its Verve Therapeutics share count unchanged in Q4 2023.
  • Verve Therapeutics made up 0.12% of GW & Wade's portfolio in Q4 2023, its #126 holding.
  • GW & Wade first reported a position in Verve Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • GW & Wade's Verve Therapeutics position peaked at $8.92M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.